The company will instead focus resources on its last remaining clinical asset, PRT7732, a chemically distinct SMARCA2 degrader.

At least 139 funded projects have focused on precision medicine since the council began awarding the grants in 2011, ...

Sarepta will sell back $50 million worth of shares to cover part of a $100 million milestone payment and its remaining shares worth $174 million.